央视网消息：冬至过后，进入数九寒天，流感高发，该如何用药呢？"感冒药+退烧药"同时服用，能让流感快速好转吗？关于流感治疗的措施与误区， 一起来了解。 感冒药退烧药同服用 这种做法不可取 北京大学第三医院儿科主任主任医师 韩彤妍：小年龄段的孩子很难用语言来表达不舒服，因为他可能烧退了，也只是最初的病毒血症的过程结束，后 面引起的咳嗽、病毒感染、肺炎、心肌炎，都可能会存在，不意味着发烧完了后，可以马上停药。 儿童流感严重程度 专家教你ABC判断法 那么，家长如何判断孩子流感严不严重，是否应该去医院看病呢？专家表示，可以通过孩子的ABC三方面来判断。韩主任表示："A就是去看孩子的活 力如何，尤其是孩子能玩玩具，即便孩子烧得高，可能烧退下来到38摄氏度，孩子都开始张罗着去玩自己的玩具，活力肯定没问题的；B是看呼吸状况，呼 吸是不是增快，或者说呼吸是否有异常的声音；C就是看循环，肤色红润还是说已经变得有点苍白，三个方面就足以判断一个小宝宝是不是该马上去医院看 病。" 专家同时提醒，一些中成药可能含有西药成分，也要当心相同药物成分的叠加。"好多中成药含有西药成分，比如说对乙酰氨基酚，它跟退烧药是同样 一类，容易造成过量， ...

本文转自【央视一套】； 专家表示，流感季如果出现感冒、发烧等不适症状，千万别乱服药，要及时就医。 儿童流感 别以退烧为停药标准 发烧、咳嗽等流感症状缓解后，能不能立刻停药？ 冬至过后，进入数九寒天，流感高发，该如何用药？感冒药和退烧药同时服用，能让流感快速好转吗？ 关于流感治疗的措施与误区，一起来了解↓↓ 感冒药和退烧药不可同服 用药叠加有风险 一些流感患者常常感冒药叠加退烧药同时服用，希望流感能快速好转。专家表示，这样做并不可取。 北京安贞医院呼吸与危重症医学科主任医师 刘泽英：很多感冒药的成分里都含有退烧药的成分，重复 用药就会增加药物剂量，导致肝肾功能下降。 此外，专家提醒，一些中成药可能含有西药成分，也要当心相同药物成分的叠加。 北京安贞医院呼吸与危重症医学科主任医师 刘泽英：比如对乙酰氨基酚跟退烧药是同一类成分，好多 人吃重了，容易造成过量，导致肝肾损害。 家长到底该如何判断孩子流感是否严重，是否应该去医院看病？北京大学第三医院儿科主任、主任医师 韩彤妍介绍，家长可以通过孩子的ABC三方面来判断↓ A：看孩子的活力如何，眼神灵活不灵活、哭声响亮不响亮，尤其是看孩子是否能玩玩具，即便烧得 高，可能烧退 ...

冬至节气的到来，标志着各地气候进入最寒冷的阶段。目前，仍处于流感等呼吸道疾病的高发期，国家卫建委提醒公众继续保持科学佩戴口罩、勤洗手、常 通风等良好卫生习惯，积极接种流感疫苗，做好个人防护，平安健康过冬。 今天下午，国家卫建委召开新闻发布会， 围绕冬至时节养生保健、流感防控和疫苗接种、呼吸系统疾病防治、常见疼痛防治、眼健康等主题，请相关方面 专家回答大家的提问。 记者提问：现在市面上能买到很多感冒药，患者自己买药的时候怎么能挑选到适合自己的药，在服药的时候有哪些注意事项？ e 4 马 艳 良 A ...

发布会现场。人民网记者 丁亦鑫摄 人民网北京12月19日电 （记者丁亦鑫）市面上能买到很多感冒药，患者自己买药的时候怎么能挑选到适合自己的药，在服药的时候有哪些注意事项？ 19日，国家卫生健康委召开新闻发布会，介绍时令节气与健康（冬至）有关情况。会上，北京大学人民医院主任医师马艳良回答了这一问题。 "如果确定是普通感冒，我们用药要记住八个字——对症治疗、安全用药。"马艳良介绍说，西药的感冒药一般有两个成份，第一种是减充血剂，常见的 是伪麻黄碱；第二种是抗过敏药，常见的是扑尔敏。这两种药物的组合就可以缓解常见的鼻子堵、打喷嚏、咳嗽、嗓子疼这类的症状。 马艳良还介绍了不同症状的用药参考。例如如果同时有发烧，超过38.5℃以上，或者是身上的酸痛、关节痛、头痛特别明显，也可以加一点退烧止痛 药，比如对乙酰氨基酚或者布洛芬。但这些感冒药经常是复方制剂的，所以一定要看它的成分，要注意这些药选一种就可以，尽量不要同时用，而且要看说 明书上的用药时间间隔，连续使用会容易过量。如果鼻塞症状特别明显，还可以加一点含有伪麻黄碱的鼻喷剂，它可以很好的收缩血管，所以鼻子可能一下 就通了，但这类药物建议使用不要超过一周，如果长期使用的话 ...

Group 1: Market Performance - The A-share market experienced rapid rotation of hot themes, with the Shanghai Composite Index down 0.42%, the Shenzhen Component Index down 0.68%, and the ChiNext Index down 0.69% at the close [1] - The total market turnover reached 1,607.3 billion [1] Group 2: Sector Performance - The pharmaceutical commercial sector showed strong performance, ranking first in the increase of sector shares, with Haiwang Biological achieving a "five consecutive limit-up" and over 290,000 sealed orders remaining at the limit-up price [1] - The Fujian sector also performed well, with stocks like Jiarong Technology and Haixin Food hitting limit-up prices [1] - Energy metals and film industry sectors, which performed well previously, experienced adjustments [1] Group 3: Market Outlook - The market is expected to remain in a phase of frequent style switching in December, primarily characterized by structural trends [1] - Key areas for potential deployment include technological innovation, domestic demand expansion, anti-involution, and stabilizing the real estate sector, with industry meetings likely to catalyze thematic trends [1] - External uncertainties, particularly the potential impact of the upcoming Federal Reserve meeting on global market liquidity, are also highlighted [1] Group 4: Health Sector Insights - The China CDC reported that the flu positivity rate among emergency and outpatient cases is close to 45%, indicating a rapid increase in flu cases, with some provinces reaching high epidemic levels [2] - According to Everbright Securities, the demand for cold medicines in Q4 is expected to exceed market expectations due to the rising trend of flu cases [2] - The introduction of multi-pathogen detection products and convenient diagnostic tools is anticipated to support the performance of related pharmaceutical companies [2]

Group 1 - The A-share market continues to exhibit a wide fluctuation pattern, with major indices experiencing weekly declines and market volume shrinking again. Financing increased slightly compared to the previous week, and stock ETFs saw net inflows, with TMT-themed ETFs being the main contributors [4] - In the fund market, pharmaceutical-themed funds performed well, while TMT-themed funds experienced significant pullbacks. Various ETFs across different investment scopes saw inflows, particularly TMT and sci-tech themed ETFs, with notable inflows into the Hang Seng Internet ETF and gold ETFs [5] - The convertible bond market saw a slight increase, with both the convertible bond and equity markets rising since the beginning of 2025, although the convertible bond market's performance was weaker. The demand for high-quality convertible bonds remains strong, and prices are at relatively high levels, necessitating careful selection [6] Group 2 - The energy storage sector is thriving, leading to price increases in lithium-ion battery materials. Short-term supply and demand are tight, with significant price hikes in lithium hexafluorophosphate. The profitability of iron phosphate is expected to recover, and prices for lithium iron phosphate materials are entering an upward channel [8] - The pharmaceutical sector saw a rise in flu-like cases, prompting attention to flu vaccines, respiratory virus testing, and cold medicine sectors. The pharmaceutical index rose by 3.29%, outperforming the CSI 300 index by 4.37 percentage points [8] - The company U (688220.SH) reported a revenue of 2.88 billion yuan for the first three quarters of 2025, a year-on-year increase of 13.42%. The net profit attributable to shareholders was a loss of 327 million yuan, a reduction in loss by 85 million yuan, with a gross margin of 25.38%, up by 1.92 percentage points year-on-year [8]

Group 1 - The pharmaceutical and biotechnology index increased by 3.29%, outperforming the CSI 300 index by 4.37 percentage points and the ChiNext index by 4.59 percentage points, ranking 5th among 31 sub-industries [4] - The Hong Kong Hang Seng Healthcare Index rose by 6.8%, surpassing the Hang Seng China Enterprises Index by 5.4 percentage points [4] Group 2 - There is a notable increase in flu-like cases since the beginning of autumn 2025, indicating a potentially severe flu season this year. In the 45th week of 2025, 21,412 flu-like case samples were tested, with positive samples primarily being A(H3N2) [5] - The change in circulating strains compared to previous years may increase the risk of breaching herd immunity, although predicting respiratory virus outbreaks remains uncertain [5] Group 3 - Future investments in the pharmaceutical sector should focus on the clinical value of drugs, addressing the clinical needs of patients, as both domestic healthcare policies and global expansion strategies increasingly emphasize clinical value [6] - Risks include unexpected cost control policies, research and development failures, insufficient policy support, and slower-than-expected promotion of commercial health insurance [6]

Investment Rating - The report maintains a rating of "Overweight" for the pharmaceutical and biotechnology sector [5]. Core Insights - The report highlights a significant increase in influenza-like illness (ILI) cases, suggesting a potential surge in demand for flu vaccines, respiratory virus testing, and cold medications [2][24]. - The report emphasizes the importance of clinical value in the pharmaceutical sector, advocating for investments in innovative drug chains and medical devices [3][27]. Summary by Sections Market Review - The pharmaceutical and biotechnology index rose by 3.29%, outperforming the CSI 300 index by 4.37 percentage points and the ChiNext index by 4.59 percentage points, ranking 5th among 31 sub-industries [1][16]. - The Hong Kong Hang Seng Medical Health Index increased by 6.8%, surpassing the Hang Seng Index by 5.4 percentage points [1][16]. Current Trends - The proportion of flu-like cases has been rising, with the ILI percentage reported at 5.5% in southern provinces and 6.1% in northern provinces, indicating a higher incidence compared to previous years [22][23]. - The report warns of a potential severe flu season in 2025, driven by changes in circulating strains and increased risks of immune evasion [2][23]. Investment Recommendations - The report suggests focusing on investment opportunities in flu vaccines, respiratory virus testing, cold medications, and special drugs due to the rising flu cases [2][24]. - Specific companies recommended for flu vaccines include Hualan Biological Engineering, Baike Biological, and Jindike; for respiratory virus testing, companies like Innotec, Shengxiang Biological, and Botao Biological are highlighted; and for cold medications, companies such as Zhongsheng Pharmaceutical, China Resources Sanjiu, and Kangyuan Pharmaceutical are suggested [2][24][26]. Key Company Earnings Forecast and Valuation - The report provides a detailed earnings forecast and valuation table for key companies, indicating a "Buy" rating for Tianjin Tasly Pharmaceutical, Innovent Biologics, and WuXi AppTec, among others [4][29]. - The earnings per share (EPS) and price-to-earnings (PE) ratios for these companies are projected to improve over the next few years, reflecting positive market sentiment [4]. Annual Investment Strategy - The report outlines a three-stage investment strategy focusing on clinical value, emphasizing the need for innovative drugs and high-end medical devices [3][27]. - It highlights the potential for growth in the innovative drug sector and the importance of domestic and international market dynamics [27][28].

Core Viewpoint - The article highlights the significant increase in influenza cases and the potential investment opportunities in related products such as vaccines, diagnostic tests, and medications due to the rising demand driven by the flu season [4][5][6]. Group 1: Influenza Situation - The incidence of influenza-like illness (ILI) has risen, with southern provinces reporting an ILI percentage of 4.6% in week 44 of 2025, up from 4.1% the previous week and higher than the same period in 2022 and 2024 [4]. - Northern provinces reported an ILI percentage of 5.1%, also showing an increase from 3.7% the previous week and higher than the same period in previous years [4]. - The flu season in 2025 is expected to be more severe than in previous years, with a notable change in circulating strains, particularly A(H3N2), which may increase the risk of breaking through herd immunity [4]. Group 2: Investment Opportunities - **Influenza Vaccines**: The low penetration rate of flu vaccines in China presents a significant growth opportunity as demand is expected to rise with the flu season approaching [5]. - **Virus Testing**: The demand for rapid and accurate diagnostic tests for respiratory viruses is anticipated to grow, benefiting companies that offer such testing products [6]. - **Cold and Specialty Medications**: The demand for cold medications is expected to increase in Q4 2025, with potential sales exceeding market expectations due to the rising flu cases and the clearing of social inventory formed during the COVID-19 pandemic [6].

Core Insights - The report from Everbright Securities indicates a significant rise in influenza cases as temperatures drop in autumn 2025, with a notable increase in public and market attention towards flu prevention and treatment products [1][2] Group 1: Influenza Trends - The incidence of influenza-like illness (ILI) has increased, with southern provinces reporting an ILI rate of 4.6% in week 44 of 2025, up from 4.1% the previous week and higher than the same period in 2022 and 2024 [1] - Northern provinces reported an ILI rate of 5.1% in the same week, also showing an increase from 3.7% the previous week and higher than the rates in 2022, 2023, and 2024 [1][2] Group 2: Investment Opportunities - **Influenza Vaccines**: The low penetration rate of flu vaccines in China presents a significant growth opportunity, especially with the expected increase in demand during the flu season. Companies to watch include Hualan Biological Engineering (301207.SZ), Baike Biological (688276.SH), and Jindike (688670.SH) [3] - **Virus Detection**: The demand for rapid and accurate diagnosis of respiratory infections is expected to boost the performance of companies in this sector. Recommended companies include Innotec (688253.SH), Shengxiang Biological (688289.SH), Botao Biological (688767.SH), and Wanfu Biological (300482.SZ) [4] - **Cold and Specialty Medicines**: The demand for cold medicines is anticipated to rise in Q4 2025, with potential sales and delivery improvements. Companies to consider include Zhongsheng Pharmaceutical (002317.SZ), China Resources Sanjiu (000999.SZ), Kangyuan Pharmaceutical (600557.SH), and others [4]